Education
About Us
Working with TipRanks
Follow Us
Rezolute (RZLT)
NASDAQ:RZLT
RZLT Stock Chart & Stats
$10.00
-$0.34(-6.35%)
At close: 4:00 PM EST
$10.00
-$0.34(-6.35%)
Day’s Range― - ―
52-Week Range$2.22 - $11.46
Previous CloseN/A
Volume107.87K
Average Volume (3M)1.54M
Market Cap
$923.10M
Enterprise Value$821.43M
Total Cash (Recent Filing)$152.19M
Total Debt (Recent Filing)$1.45M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Feb 11, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding92,727,530
10 Day Avg. Volume1,424,407
30 Day Avg. Volume1,535,863
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio-4.91
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-102.68K
Enterprise Value/Ebitda-10.13
Forecast
1Y Price Target
$16.14Price Target Upside61.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.9
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical SuccessDr. Thornton's insight supports a high likelihood of clinical success for ersodetug and favorable market adoption upon FDA approval.
Market PotentialRZLT is optimistic that up to 50% of diazoxide responsive patients could eventually transition to ersodetug based on feedback from physicians and patient communities.
Regulatory ApprovalThe FDA's acceptance of the streamlined Ph3 design allows for an open-label study in approximately 16 patients, simplifying the study process.
Bears Say
Clinical Study EffectsDr. Thornton cautioned that participation in a clinical study alone may lead to improvement in hypoglycemia control due to more rigorous monitoring creating positive effects.
Conflict Of InterestInvestors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.
Data InterpretationDr. Thornton cautioned that a placebo effect could be possible, emphasizing the importance of careful data interpretation when Ph3 top-line data become available.
Rezolute News
RZLT FAQ
What was Rezolute’s price range in the past 12 months?
Rezolute lowest stock price was $2.21 and its highest was $11.46 in the past 12 months.
What is Rezolute’s market cap?
Rezolute’s market cap is $923.10M.
When is Rezolute’s upcoming earnings report date?
Rezolute’s upcoming earnings report date is Feb 11, 2026 which is in 89 days.
How were Rezolute’s earnings last quarter?
Rezolute released its earnings results on Nov 06, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.242 by $0.062.
Is Rezolute overvalued?
According to Wall Street analysts Rezolute’s price is currently Undervalued.
Does Rezolute pay dividends?
Rezolute does not currently pay dividends.
What is Rezolute’s EPS estimate?
Rezolute’s EPS estimate is -0.2.
How many shares outstanding does Rezolute have?
Rezolute has 92,727,530 shares outstanding.
What happened to Rezolute’s price movement after its last earnings report?
Rezolute reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.242. Following the earnings report the stock price went up 12.083%.
Which hedge fund is a major shareholder of Rezolute?
Currently, no hedge funds are holding shares in RZLT
Rezolute Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.14 (61.40% Upside)
$16.14 (61.40% Upside)
Blogger Sentiment
Bullish
RZLT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
71.82%
12-Months-Change
Fundamentals
Return on Equity
-59.23%
Trailing 12-Months
Asset Growth
28.56%
Trailing 12-Months
Company Description
Rezolute
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
RZLT Stock 12 Month Forecast
Average Price Target
$16.14
▲(61.40% Upside)
Technical Analysis
Ownership Overview
10.45% Insiders
39.03% Mutual Funds
0.61% Other Institutional Investors
40.51% Public Companies and Individual Investors